(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
Q32 Bio Inc (NASDAQ:QTTB) saw its stock skyrocket 94% in premarket trading on Monday after revealing that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics (NASDAQ:AKBA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback